AI-Powered Drug Discovery

Isomorphic Labs (London, spun off from Google DeepMind) is applying AlphaFold's protein structure prediction to drug discovery. The company raised $600M (March 2025, led by Thrive Capital) to build an AI drug-design engine that predicts how candidate molecules interact with biological targets before any physical experiments.

The technology leverages AlphaFold's Nobel Prize-winning breakthrough: predicting protein 3D structures from amino acid sequences with atomic-level accuracy. Isomorphic extends this to predict drug-protein interactions, dramatically reducing the time and cost of identifying promising drug candidates. The company is preparing to enter clinical trials with AI-designed drugs.

The UK's position in computational biology is unmatched: DeepMind (London), the Wellcome Sanger Institute, the Francis Crick Institute, and Oxford/Cambridge research clusters create the deepest concentration of structural biology and AI talent in the world. Isomorphic represents the convergence of these two British strengths — AI and life sciences — into a commercially viable drug discovery platform that could reshape pharmaceutical R&D globally.